De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study.
about
Pseudomonas aeruginosa ventilator-associated pneumonia managementManagement of neutropenic patients in the intensive care unit (NEWBORNS EXCLUDED) recommendations from an expert panel from the French Intensive Care Society (SRLF) with the French Group for Pediatric Intensive Care Emergencies (GFRUP), the French SCollaborative approach of individual participant data of prospective studies of de-escalation in non-immunosuppressed critically ill patients with sepsis.Evaluation of early antimicrobial therapy adaptation guided by the BetaLACTA® test: a case-control study.Combatting resistance in intensive care: the multimodal approach of the Spanish ICU "Zero Resistance" program.How to treat severe infections in critically ill neutropenic patients?Year in review in Intensive Care Medicine 2014: III. Severe infections, septic shock, healthcare-associated infections, highly resistant bacteria, invasive fungal infections, severe viral infections, Ebola virus disease and paediatrics.A Simulation Study Reveals Lack of Pharmacokinetic/Pharmacodynamic Target Attainment in De-escalated Antibiotic Therapy in Critically Ill PatientsDiagnostic performance of matrix-assisted laser desorption ionisation time-of-flight mass spectrometry in blood bacterial infections: a systematic review and meta-analysis.Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearanceBenefits and unintended consequences of antimicrobial de-escalation: Implications for stewardship programsEfficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.De-escalating Antibiotic Use in the Inpatient Setting: Strategies, Controversies, and Challenges.Characteristics and outcomes of anti-infective de-escalation during health care-associated intra-abdominal infectionsNeutropenic Sepsis in the ICU: Outcome Predictors in a Two-Phase Model and Microbiology Findings.Bloodstream infections in the Intensive Care Unit.Bloodstream infections in neutropenic cancer patients: A practical update.ACVIM consensus statement on therapeutic antimicrobial use in animals and antimicrobial resistance.Determinants of Deescalation Failure in Critically Ill Patients with Sepsis: A Prospective Cohort Study.(1, 3)-β-D-glucan assay for diagnosing invasive fungal infections in critically ill patients with hematological malignancies.De-escalation empirical antibiotic therapy improved survival for patients with severe aplastic anemia treated with antithymocyte globulin.Antimicrobial stewardship of β-lactams in intensive care units.Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria.Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric).Pros and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting.A Systematic Review of the Definitions, Determinants, and Clinical Outcomes of Antimicrobial De-escalation in the Intensive Care Unit.Targeted simplification versus antipseudomonal broad-spectrum beta-lactams in patients with bloodstream infections due to Enterobacteriaceae (SIMPLIFY): a study protocol for a multicentre, open-label, phase III randomised, controlled, non-inferioritImpact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia.The Intensive Care Medicine research agenda on critically ill oncology and hematology patients.Severity of Acute Respiratory Distress Syndrome in haematology patients: long-term impact and early predictive factors.Understanding the risk for infection in patients with neutropenia.Antimicrobial resistance in Gram-negative rods causing bacteremia in hematopoietic stem cell transplant patients: intercontinental prospective study of Infectious Diseases Working Party of the European Bone Marrow Transplantation group.Antimicrobial de-escalation in septic cancer patients: is it safe to back down?De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial.The case for de-escalation in antimicrobial therapy: time to change our strategy in the management of septic shock?Impact of de-escalation on ICU patients' prognosis.Focus on adequate antimicrobial treatment and de-escalation in the ICU.Impact of de-escalation of beta-lactam antibiotics on the emergence of antibiotic resistance in ICU patients: a retrospective observational study.[Antibiotic stewardship : Measures for optimizing prescription of anti-infective agents].Need for a biomarker to de-escalate antimicrobial empirical therapy.
P2860
Q26768365-524F1198-B568-4D5D-8F5E-6B692B10EA50Q27320711-4A91B05F-1E7A-4B84-98AA-3F20A5A48003Q31171527-67C5EBCD-127C-4557-8761-0169D3E107C4Q33846503-CA0E524F-B447-45A0-9FB5-D90CC7A30C3FQ35181034-9F1CCA8F-F2B7-42D6-90CD-0B65C19F900BQ35457899-E7F1DE05-D24A-4EAC-AF96-16DA4D25332BQ35816268-2F5AA93E-232F-4DFA-ACE8-90BD7B69EAC3Q35860038-9B92407F-BCC8-4F77-8B49-75A8B65BC9FAQ36000312-EE5B20ED-7434-489E-83BF-8DD21346488FQ36089167-6F4C5C18-59FC-4220-884E-9A342C2E4426Q36275773-28AF6B75-0296-49B5-AD64-B5B9831436D2Q36294413-1389E4FB-F22C-4FFE-8861-EA289A28F5D8Q36331033-15F3F654-7220-4778-95F9-12B0988DC405Q36774787-D501011E-1FA2-45FB-A0E5-BCE38371ABF8Q36855541-B9816DD3-CD84-4EBC-BB1A-766B9F8D10BAQ36913336-865C1AF6-67DE-400B-A659-E1397BE926C3Q36913345-8DBE5D2C-452B-4F4F-B505-C0DC94375B82Q36975171-30224707-E109-4CEB-825C-5FCB8AB3AAA7Q37132283-78ADA69A-F702-4CAF-A23E-A743307E830AQ37225323-4A68315B-6973-4644-8519-1FB4C2E74BF7Q37646566-3744F27C-0829-42E4-9DCA-237A8EB9D961Q38198157-E91A42B8-1EB8-40AF-A8D6-C1E62BBA7A56Q38384662-C2550E58-A525-47DE-9FC1-92CF13678CA8Q38528292-356719F1-1B56-4E49-A7F8-5CD41AC8C8C1Q38550893-A987B445-BC36-47F2-85CF-24256ACAA1C8Q38679343-C8662705-0F31-419F-9119-8791A4F4E666Q38732091-0826BC30-55BF-4167-97AD-0C210FA4183DQ39231468-EDE98DE7-827E-4058-9A50-80E2799A6962Q39446746-8F3EC5FA-BE4A-4A96-BA46-BB893DBB83DBQ40612816-D074CD0C-A56D-4D2F-B8E0-118EEE4D9953Q41110370-68CF8714-E452-4AD3-BE4D-4B62A8E8E2E1Q41987005-3F1C05EA-5780-4C0E-BBB9-6F16A5E7AF85Q43240867-7443C0FF-95DA-4972-8712-D1DFB1AA1BD5Q44019769-427AE1B7-2546-464A-B733-60DC44DF0F92Q45049663-28A43A5D-0DED-43A2-84EB-0EDE9684DE41Q46701245-2C060375-065C-4FF4-ABD6-ECC1F58C329CQ48328989-B334AE8F-9574-4233-90EE-B4EB8A2EB293Q49061695-685ADDA2-C732-44FD-8EA6-00957F4EA5DCQ50128182-035F9F1D-0527-408A-A824-79F19583CBF6Q54501341-B943CDEF-7E95-4107-9021-6D60FADFB866
P2860
De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
De-escalation of antimicrobial ...... s from an observational study.
@en
De-escalation of antimicrobial ...... s from an observational study.
@nl
type
label
De-escalation of antimicrobial ...... s from an observational study.
@en
De-escalation of antimicrobial ...... s from an observational study.
@nl
prefLabel
De-escalation of antimicrobial ...... s from an observational study.
@en
De-escalation of antimicrobial ...... s from an observational study.
@nl
P2093
P2860
P1476
De-escalation of antimicrobial ...... ts from an observational study
@en
P2093
Antoine Sannini
Colombe Saillard
Géraldine Slehofer
Jean-Louis Blache
Jean-Paul Brun
Jérôme Lambert
Laurent Chow-Chine
Marc Leone
Marion Faucher
Norbert Vey
P2860
P2888
P356
10.1007/S00134-013-3148-9
P50
P577
2014-01-01T00:00:00Z